Skip to main content

Table 5 Pharmacokinetic parameters after oral administration of vorinostat suspension (pure drug) and optimized vorinostat-loaded SMEDDS (F7)

From: Improved oral bioavailability of poorly water-soluble vorinostat by self-microemulsifying drug delivery system

Parameters (units) Group I (SMEDDS 10 mg/kg) Group II (control)
API suspension 10 mg/kg)
Cmax (ng/mL) 24.62 ± 0.28* 15.50 ± 0.29
Tmax (h) 2.17 ± 0.02* 1.23 ± 0.09
AUC(0−∞) (ng/mL h) 1325.33 ± 16.28* 365.00 ± 12.76
t1/2 (h) 7.66 ± 0.18* 15.50 ± 0.28
MRT(0−∞) (h) 11.88 ± 0.08* 22.69 ± 0.36
F# (%) 363.10
  1. Values are expressed as mean ± SEM of 6 animals. Symbol represents the statistical significance performed by ANOVA, followed by Tukey–Kramer’s multiple comparison tests
  2. *p < 0.001 indicates the comparison of group I (SMEDDS) with group II (API suspension) treated animals. Maximum plasma concentration (Cmax). Time of maximum concentration (Tmax), area under curve extrapolated to infinity (AUC(0−∞)), elimination half-life (t1/2), mean residence time when the drug concentration profile is extrapolated to infinity (MRT(0−∞)), relative bioavailability (F#), active pharmaceutical ingredient-Vorinostat (API-Vorinostat)